Omeros Corporation - Common Stock (OMER)

The company is on the brink of commercializing a unique medication.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.

The drug was approved for use in adults and children aged two years and older.

The FDA decision on Narsoplimab, its treatment for post–stem cell and bone marrow transplant complications, is officially due on December 26.

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.

Omeros (OMER) Q3 2025 Earnings Call Transcript

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels.

In today's session, these stocks are experiencing unusual volume.

Unusual volume stocks are being observed in Thursday's session.

Find out if the deal Omeros announced is enough of a reason to buy this stock.

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31.

In a dramatic turn of events that sent shockwaves through the biotechnology sector, Omeros Corporation (NASDAQ: OMER) witnessed its stock catapult by an astounding nearly 150% after announcing a colossal licensing agreement with pharmaceutical titan Novo Nordisk (CPH: NOVO B). The deal, potentially valued at up to $2.1 billion,